Clinical trial GRASPA-TNBC-2018-02
A Randomized Phase 2/3 Study of Eryaspase in Combination with Gemcitabine and Carboplatin Chemotherapy versus Chemotherapy Alone As First-Line Treatment in Patients with Metastatic or Locally Recurrent Triple-Negative Breast Cancer
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial closed |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2/3 |
| Academic trial | Non |
| Sponsor | Erytech |
| EudraCT Identifier | 2018-002211-10 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03674242 |
| Inclusion criteria | Triple negative |
| Last update |